Central statistical monitoring: Detecting fraud in clinical trials

Clinical Trials

Volumn 10, Issue 2, 2013, Pages 225-235

  Pogue, Janice M ^a,b   Devereaux, P J ^a   Thorlund, Kristian ^a   Yusuf, Salim ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); FALSE POSITIVE RESULT; FRAUD; HUMAN; MONITORING; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; VALIDATION STUDY;

CLINICAL TRIALS AS TOPIC; FACTOR ANALYSIS, STATISTICAL; FRAUD; HUMANS; MODELS, STATISTICAL; MULTICENTER STUDIES AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 84876537291     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774512469312     Document Type: Article

References (34)

1. Baigent C, Harrell F, Buyse M, Emberson J, Altman D.. Ensuring trial validity by data quality assurance and diversification of monitoring methods. Clin Trials. 2008 ; 5: 49-55
2. Buyse M, George S, Evans S, et al. The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. Stat Med. 1999 ; 18: 3435-51
3. DeMets D.. Distinctions between fraud, bias, errors, misunderstanding, and incompetence. Clin Trials. 1997 ; 18: 637-50
4. Eisenstein E, Collins R, Cracknell B, et al. Sensible approaches for reducing clinical trials costs. Clin Trials. 2008 ; 5: 75-84
5. Knatterud G, Rockhold F, George S, et al. Guidelines for quality assurance in multicenter trials: A position paper. Control Clin Trials. 1998 ; 19: 477-93
6. Neaton J, Bartsch G, Broste S, et al. A case of data alteration in the Multiple Risk Factor Intervention Trial (MRFIT). Control Clin Trials. 1991 ; 12: 731-40
7. Peto R, Collins R, Sackett D, et al. The trials of Dr. Bernard Fisher: A European perspective on an American episode. Control Clin Trials. 1997 ; 18: 1-13
8. Yusuf S, Bosch J, Devereaux P, et al. Sensible guidelines for the conduct of large randomized trials. Clin Trials. 2008 ; 5: 38-39
9. Morrison B, Cochran C, White J, et al. Monitoring the quality of conduct of clinical trials: A survey of current practices. Clin Trials. 2011 ; 8: 342-49
10. Shapiro M, Charrow R.. The role of data audits in detecting scientific misconduct: Results of the FDA program. JAMA. 1989 ; 261: 2505-11
11. Weiss R, Vogelzang N, Peterson B, et al. A successful system of scientific data audits for clinical trials: A report from the Cancer and Leukemia Group B. JAMA. 1993 ; 270: 459-64
12. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. New York: Springer ; 2010 :
13. Eisenstein E, Lemons P, Tardiff B, et al. Reducing the costs of phase III cardiovascular clinical trials. Am Heart J. 2005 ; 149: 482-88
14. Bailey K.. Detecting fabrication of data in a multicenter collaborative animal study. Control Clin Trials. 1991 ; 12: 741-52
15. Christian M, McCabe M, Korn E, et al. The National Cancer Institute audit of the National Surgical Adjuvant Breast and Bowel Project B-06. N Engl J Med. 1995 ; 333: 1469-74
16. Ranstam J, Buyse M, George S, et al. Fraud in medical research: An international survey of biostatisticians. Control Clin Trials. 2000 ; 21: 415-27
17. Swazey J, Anderson M, Lewis K.. Ethical problems in academic research. Am Sci. 1993 ; 81: 542-52
18. White C.. Suspected research fraud: Difficulties of getting the truth. BMJ. 2005 ; 331: 281-88
19. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: Randomized placebo-controlled trial. Lancet. 2005 ; 366: 1607-21
20. Al-Marzouki S, Evans S, Marshall T, Roberts I.. Are these data real? Statistical methods for the detection of data fabrication in clinical trials. BMJ. 2005 ; 331: 267-70
21. European Stroke Prevention Study 2. Efficacy and safety data. J Neurol Sci. 1997 ; 151: S1 - S77
22. SchraeplerJWagnerG. Identification, characteristics and impact of faked interviews in surveys. IZA DP No. 969, 2011. The Institute for the Study of Labor (IZA), www.iza.org.
23. Murphy J, Eyerman J, McCue C, Hottinger C, Kenner J.. Interviewer falsification detection using data mining. Proceedings of Statistics Canada Symposium ; 2005 Ottawa, Ontario, Canada ; 2005..
24. Svolba G, Bauer P.. Statistical quality control in clinical trials. Control Clin Trials. 1999 ; 20: 519-30
25. Taylor R, McEntegart D, Stillman E.. Statistical techniques to detect fraud and other data irregularities in clinical questionnaire data. Drug Inform J. 2002 ; 36: 115-25
26. Devereaux P, Yang H, Yusuf S, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): A randomised controlled trial. Lancet. 2008 ; 371: 1839-47
27. Benford F.. The law of anomalous numbers. Proc Am Phil Soc. 1938 ; 78: 551-72
28. Preece D.. Distribution of final digits in data. Statistician. 1981 ; 30: 31-60
29. Cary, NC: ; 2002.
30. Sullivan L, Massaro J, D'Agostino R. Presentation of multivariate data for clinical use: The Framingham Study risk score function. Stat Med. 2004 ; 23: 1631-60
31. Evans S. Fraud and Misconduct in Medical Research. Lock S Wells F, ed. London: BMJ Publishing Group ; 1996: 226-39.
32. Furnival G, Wilson R.. Regression by leaps and bounds. Technometrics. 1974 ; 16: 499-511
33. Hosmer DWJ, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons ; 1989 :
34. Effect of an angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high-risk patients. N Engl J Med. 2000 ; 324: 145-53